Corporate alliances
The Belfer Center partners with pharmaceutical and biotechnology companies to transform basic and preclinical research into therapeutic breakthroughs.
Daiichi Sankyo
Accelerating the development of new therapeutic strategies for patients with lung cancer
AstraZeneca
Addressing drug-resistant lung cancer and creating models to develop the next generation of drugs
Array BioPharma
Advancement of innovative immune-therapeutics
Janssen
Identifying the most effective combinations of next-generation immunotherapies to treat lung cancer patients
Evotec AG
Discovering new oncology therapies that target epigenetic mechanisms
New Company
New text
Sanofi
Discovery and development of the next generation of targeted cancer therapeutic
Merck & Co
Identifying promising targets to develop novel therapeutic candidates
Academic alliances
The Belfer Center collaborates with academic physician/scientists conducting basic and translational oncology research and clinical studies.
David Barbie, MD
Physician, Thoracic Oncology, Dana-Farber Cancer Institute
A collaboration to conduct immune profiling of non-small cell lung cancer and functional studies in organotypic tumor spheroids
Raphael Bueno, MD
Chief, Division of Thoracic Surgery, Brigham and Women’s Hospital
A collaboration utilizing flow cytometric and scRNAseq-based technologies to understand mechanisms of response and resistance to immune- and targeted therapeutics in mesothelioma and non-small cell lung cancer
Alan D’Andrea, MD
Director, Susan F. Smith Center for Women’s Cancers and the Center for DNA Damage and Repair, Dana-Farber Cancer Institute
A collaboration to explore DNA damage response and immunological mechanisms to develop therapeutic approaches for ovarian cancer patients
Pasi Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
A collaboration to develop novel targeted therapies for non-small cell lung cancer patients and explore drug resistance with lung patient-derived xenografts (PDX)
Jochen Lorch, MD, MS and Glenn Hanna, MD
Dr. Lorch: Director, Thyroid Cancer Center and Endocrine Cancer Treatment Center
Dr. Hanna: Physician, Head and Neck Cancer
Dana-Farber Cancer Institute
A collaboration for immune profiling of patients receiving immune checkpoint blockade and next-generation immunotherapeutics to identify predictive biomarkers and mechanisms of acquired resistance
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology, Susan F. Smith Center for Women’s Cancer, Dana-Farber Cancer Institute
A collaboration to develop novel therapeutics for ovarian cancer utilizing an ovarian patient-derived xenografts (PDX) platform